Clinical trials: Cardiothoracic Surgery
Cardiothoracic Surgery, Vascular Surgery
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery
This study will evaluate the safety and efficacy of ABT-719 in patients undergoing high risk major surgery.
- Trial name
- NCT01897519
- Testing
- ABT-719
- Where
- 23 sites in United States, Denmark
- Volunteers
- 56 people
- Sponsor
- AbbVie
Bleeding Active
Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding
The study is to evaluate the effectiveness and safety of CELSTAT vs active control.
- Trial name
- CELSTAT (NCT02640235)
- Testing
- CELSTAT, Surgicel Original
- Where
- 25 sites in United States, Czechia and 2 more
- Volunteers
- 260 people
- Sponsor
- Baxter Healthcare Corporation
AKI - Acute Kidney Injury, Cardiac Surgery
Urine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO®
This prospective observational study evaluates the real-time urine output response to fluid therapy and diuretics in cardiothoracic intensive care unit (CTICU) patients monitored with the FIZE kUO® device.
- Conditions
- AKI - Acute Kidney Injury, Cardiac Surgery, Fluid Therapy, Hemodynamic Instability
- Trial name
- NCT07022314
- Testing
- FIZE kUO®
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- FIZE Medical ltd
Atrial Fibrillation
Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery
SGLT2 inhibitors are oral anti-diabetic medications that were found to improve cardiorenal outcomes in patients with type 2 diabetes mellitus (DM), chronic heart failure with reduced and preserved ejection fraction, and chronic…
- Trial name
- NCT06251453
- Testing
- SGLT2 inhibitor
- Where
- 2 sites in Qatar
- Volunteers
- 3,280 people
- Sponsor
- Hamad Medical Corporation
Acute Coronary Syndrome
Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery
The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine…
- Trial name
- CyTation (NCT04625764)
- Testing
- Blood sampling and analysis
- Where
- 4 sites in Germany, Luxembourg
- Volunteers
- 6 people
- Sponsor
- CytoSorbents Europe GmbH
Hemorrhage
SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
This is a prospective, single arm, multicentre, multispecialty, post market, clinical study evaluating SURGICEL Powder as an adjunct to achieve haemostasis (control bleeding) when conventional methods of control are impractical…
- Trial name
- NCT03762200
- Testing
- SURGICEL Powder
- Where
- 8 sites in Belgium, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Ethicon, Inc.
Emergent Cardiothoracic Surgery, Bleeding
Ticagrelor CytoSorb Hemoadsorption
TISORB is a study to show that the CytoSorb device removes ticagrelor from blood during surgery in patients who need emergency surgery on their heart.
- Conditions
- Emergent Cardiothoracic Surgery, Bleeding, Drug Removal
- Trial name
- TISORB (NCT04131959)
- Testing
- CytoSorb 300 mL device
- Where
- 8 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- CytoSorbents, Inc
Renal Impairment After Cardiac Surgery, Renal Impairment
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively.
- Conditions
- Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury
- Trial name
- GRADIENT (NCT07017933)
- Testing
- Renal assist device
- Where
- 7 sites in United States, Poland
- Volunteers
- 124 people
- Sponsor
- 3ive Labs
Hemostasis
HEMOBLAST Pivotal Clinical Investigation
The purpose of this prospective, randomized, controlled study is to evaluate the safety and efficacy of a new hemostatic device (HEMOBLAST™ Bellows) compared to a control device, absorbable gelatin sponge USP with thrombin.
- Trial name
- NCT02780869
- Testing
- HEMOBLAST Bellows, Absorbable gelatin sponge, USP with thrombin
- Where
- 17 sites in United States
- Volunteers
- 258 people
- Sponsor
- Biom'Up France SAS
Cardiothoracic Surgery
Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations
The purpose of this study is to evaluate the performance of HEMOBLAST™ compared to FLOSEAL in cardiothoracic operations.
- Trial name
- NCT03725098
- Testing
- HEMOBLAST Bellows, FLOSEAL
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Biom'Up France SAS
Patient With Clinically Indicated Invasive Monitoring
ClearSight System CHN Study
The purpose of this clinical trial is to demonstrate that cardiac output (CO) as determined with the Clinical Platform (Model:EV1000A, Software Version:1.9) in a noninvasive manner is comparable to CO as determined by Pulmonary…
- Trial name
- NCT03807622
- Testing
- EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System
- Where
- 3 sites in China
- Volunteers
- 125 people
- Sponsor
- Edwards Lifesciences
Post Operative Pain
A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves
This is a retrospective and prospective, multicenter, observational patient registry to record outcomes from patients undergoing cryoablation of the intercostal nerves (cryoanalgesia) for post-operative pain management.
- Trial name
- REDUCE (NCT05110989)
- Testing
- AtriCure Cryo Nerve Block (cryoNB) Device Family
- Where
- 11 sites in United States, Austria and 3 more
- Volunteers
- 5,000 people
- Sponsor
- AtriCure, Inc.
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC